Company / PP&E (Net)
Coherus Oncology, Inc. PP&E (Net) History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$5.8M
FY2019
5-year range
$5.8M / $12.8M
FY2015-FY2019
Trend
-12.3%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $13M to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2019 with a 5-year CAGR of +5.5%.
Declined from $13M to $6M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -18.5%
- 5-Year CAGR
- +5.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +5.5%, indicating consistent growth.
- In FY2019, pp&e (net) decreased 12.3% year-over-year.
- Peak pp&e (net) was recorded in FY2017.
- Lowest pp&e (net) in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -0.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2019 | $5.8M | -12.3% |
| FY2018 | $6.7M | -47.9% |
| FY2017 | $12.8M | +18.6% |
| FY2016 | $10.8M | +2.6% |
| FY2015 | $10.5M | +134.9% |
| FY2014 | $4.5M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026